Related Experiment Videos
[Prevention using a Pseudomonas immunoglobulin in burn patients]
Abstract:
Pseudomonas aeruginosa belongs to the most frequent pathogens isolated from patients with burns. In a mouse model for artificial burns it was found that prophylactic administration of a hyperimmune globulin with antibody titres against P. aeruginosa (Fisher immunotypes 1, 2, 4 and 6) reduced mortality. Therefore, the prophylactic administration of Pseudomonas immunoglobulin was examined in a prospective randomized study in two groups of 13 patients each. Severely burned patients with at least second degree burns over 30% to 70% of the total body surface area received 250 mg Pseudomonas immunoglobulin/kg body weight by the intravenous route between days 3 and 13. After treatment, plasma IgG levels were significantly raised between days 7 and 16 as compared to the controls, yet the incidence of infections caused by P. aeruginosa was not reduced. However, only two of the six infected patients, developed septicaemia, whereas in the control group, local Pseudomonas infection led to septicaemia in five out of seven patients. The number of septicaemic Staphylococcus aureus infections was also lower in patients on immunoglobulin prophylaxis, with two cases compared to four cases in the control group. Due to the limited number of cases studied, statistically significant results could not be obtained, however, there was a positive trend in favour of Pseudomonas immunoglobulin treatment.
Insights
Pseudomonas immunoglobulin prophylaxis in burn patients did not reduce P. aeruginosa infections but showed a trend towards lower mortality from sepsis. Further studies are needed to confirm these findings.
Area of Science:
- Immunology
- Infectious Diseases
- Burn Care
Background:
- Pseudomonas aeruginosa is a common pathogen in burn patients.
- A mouse model suggested hyperimmune globulin against P. aeruginosa reduces mortality.
- Burn patients are at high risk for P. aeruginosa infections and sepsis.
Purpose of the Study:
- To evaluate the prophylactic effect of Pseudomonas immunoglobulin in severely burned patients.
- To assess the impact of Pseudomonas immunoglobulin on P. aeruginosa infection rates and sepsis development.
- To analyze changes in plasma IgG levels following immunoglobulin administration.
Main Methods:
- Prospective randomized study with two groups of 13 severely burned patients.
- Intravenous administration of 250 mg/kg Pseudomonas immunoglobulin between days 3 and 13.
- Monitoring of P. aeruginosa infection incidence, sepsis development, and plasma IgG levels.
Main Results:
- Plasma IgG levels were significantly increased in the treatment group compared to controls.
- The incidence of P. aeruginosa infections was not reduced.
- A trend towards lower rates of sepsis from P. aeruginosa and Staphylococcus aureus infections was observed.
Conclusions:
- Pseudomonas immunoglobulin prophylaxis did not significantly decrease P. aeruginosa infection rates in burn patients.
- A positive trend suggested reduced mortality from sepsis in patients receiving immunoglobulin.
- Larger studies are required to establish the efficacy of Pseudomonas immunoglobulin in burn wound management.